跳到正文
原文
Nature 综合主刊· Lara McGrath·· 26 天前精选AI 评分84

NeoCOAST-2:可切除肺癌中ctDNA清除与无事件生存率的关系

ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2

AI 导读

NeoCOAST-2试验显示,ctDNA清除与无事件生存率延长相关。ctDNA清除的患者有更佳的无事件生存率,联合评估ctDNA清除和病理完全缓解可能改善风险分层。

推荐理由

研究发现ctDNA清除与无事件生存率延长相关,提示联合评估ctDNA清除和病理完全缓解可能改善风险分层。

正文 · 原文
  • Article
  • Published: 25 October 2026

Nature (2026) Cite this article

We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.

Abstract

Patients with resectable non-small cell lung cancer (NSCLC) remain at high risk of relapse despite perioperative treatment1-3. NeoCOAST-2 (NCT05061550), a phase 2, randomised platform trial, tested novel perioperative treatments in patients with stage IIA–IIIB NSCLC. At primary analysis, combining standard chemotherapy plus durvalumab (anti-PD-L1 antibody) with oleclumab (Arm 1, n = 76), monalizumab (Arm 2, n = 72) or datopotamab deruxtecan (Dato-DXd; Arm 4, n = 54) resulted in pathological complete response (pCR) rates of 20.3%, 25.7%, and 35.2%, respectively4. Here, we present the first report of prespecified secondary endpoints of event-free survival (EFS) and circulating tumour DNA (ctDNA) clearance, and exploratory analyses of associations between ctDNA dynamics and clinical outcomes. The 24-month EFS rates were 70.5%, 75.7% and 77.9% in Arms 1, 2 and 4, respectively. Using a tumour-agnostic assay, ctDNA clearance at neoadjuvant Cycle 3 Day 1 was highest in Arm 4 (50.9%, 54.5%, and 72.5% in each arm, respectively). ctDNA clearance correlated with prolonged EFS versus non-clearance (pooled hazard ratio (HR) 0.22; 95% CI = 0.11–0.45, P = 0.0000443). Patients with both ctDNA clearance and pCR had favourable EFS outcomes versus those with neither (EFS HR 0.10, 95% CI = 0.02–0.42, P = 0.002). These findings suggest combined assessment of ctDNA clearance and pCR may improve risk stratification, and that the numerically highest pCR4 and EFS rates with the Dato-DXd combination warrant further evaluation.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

27.99 € / 30 days cancel any time

Learn more

Rent or buy this article

Prices vary by article type

$1.95 to $39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Author information

Authors and Affiliations

  1. Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, MA, USA

    Lara McGrath

  2. Translational Medicine, Early Data Science, Oncology R&D, AstraZeneca, Cambridge, UK

    Gozde Kar

  3. Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy

    Laura Bonanno

  4. Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy

    Laura Bonanno

  5. Univ Rouen Normandie, LITIS Lab QuantIF team EA4108, CHU Rouen, Department of Pneumology and Inserm CIC-CRB 1404, Rouen, France

    Florian Guisier

  6. Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain

    Amelia Insa

  7. Division of Thoracic Surgery, University of Montréal, Montréal, Quebec, Canada

    Moishe Liberman

  8. CETOC - CHUM Endoscopic Tracheobronchial and Oesophageal Center, Centre Hospitalier de l’Université de Montréal, Montreal, Quebec, Canada

    Moishe Liberman

  9. Pneumology Department, Hôpital d’Instruction des Armées Sainte-Anne, Toulon, France

    Olivier Bylicki

  10. Department of Radiation Oncology, University of Florence, Florence, Italy

    Lorenzo Livi

  11. Department of Thoracic Oncology, Dupuytren University Hospital, Limoges, France

    Thomas Egenod

  12. Department of Medical Oncology, CH de Cornouaille, Quimper, France

    Romain Corre

  13. Department of Internal Medicine, Seoul National University College of Medicine and Seoul National Hospital, Seoul, South Korea

    Dong-Wan Kim

  14. Hospital de A Coruña, Sergas, A Coruña, Spain

    Maria Rosario Garcia Campelo

  15. Puerta de Hierro University Hospital, Majadahonda, Spain

    Mariano Provencio Pulla

  16. Department of Medical Oncology, The Catholic University of Korea, St. Vincent’s Hospital, Seoul, South Korea

    Byoung Yong Shim

  17. Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy

    Giulio Metro

  18. Department of Medical Oncology, Hôpital Foch, Suresnes, France

    Jaafar Bennouna

  19. Early Clinical Development, Oncology R&D, AstraZeneca, Cambridge, MA, USA

    Agata A. Bielska & Italia Grenga

  20. Early Clinical Development, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA

    Alula R. Yohannes & Joanna Shaju

  21. Early Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, MA, USA

    Yun He

  22. Early Clinical Programs, Oncology R&D, AstraZeneca, Cambridge, UK

    Adam Dowson

  23. Department of Thoracic Surgery, McGill University, Montreal, Quebec, Canada

    Jonathan Spicer

  24. Trinity St. James’s Cancer Institute, School of Medicine, Trinity College Dublin, Dublin, Ireland

    Patrick M. Forde

  25. Department of Thoracic-Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Tina Cascone

Authors

  1. Lara McGrath
  2. Gozde Kar
  3. Laura Bonanno
  4. Florian Guisier
  5. Amelia Insa
  6. Moishe Liberman
  7. Olivier Bylicki
  8. Lorenzo Livi
  9. Thomas Egenod
  10. Romain Corre
  11. Dong-Wan Kim
  12. Maria Rosario Garcia Campelo
  13. Mariano Provencio Pulla
  14. Byoung Yong Shim
  15. Giulio Metro
  16. Jaafar Bennouna
  17. Agata A. Bielska
  18. Alula R. Yohannes
  19. Joanna Shaju
  20. Yun He
  21. Adam Dowson
  22. Italia Grenga
  23. Jonathan Spicer
  24. Patrick M. Forde
  25. Tina Cascone

Corresponding author

Correspondence to Tina Cascone.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McGrath, L., Kar, G., Bonanno, L. et al. ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2. Nature (2026). https://doi.org/10.1038/s41586-026-11328-3

Download citation

  • Received: 24 June 2026

  • Accepted: 16 October 2026

  • Published: 25 October 2026

  • DOI: https://doi.org/10.1038/s41586-026-11328-3

来源:Nature 综合主刊 · nature.com